Search trials – HealthDB

Активни:

Намерени 282 изпитвания Стр. 1 от 15

Recruiting Phase 2

Colchicine to Quench the Inflammatory Response after Deep Vein Thrombosis: The CONQUER-DVT Randomized Controlled Trial

deep vein thrombosis

Trial status: Authorised Proportion of patients with PTS (Villalta score ≥5) at 6 months, Proportion of patients according to the following PTS severity categories based on Villalta score category: mild (Villalta Score 5-9), moderate (Villalta score 10-14), severe (Villalta score ≥15 or presence of ulcer) at 6 and 12 months, Mean Villalta score and mean change from baseline (based on continuous Villalta score) at 6 and 12 months to estimate the severity of PTS, Incidence rate of recurrent venous thromboembolism (VTE) during follow-up (up to 12 months), Incidence rate of arterial thromboembolism (ATE) during follow-up (up to 12 months), Incidence rate of composite of adverse vascular events (comprising PTS, recurrent VTE, ATE) during follow-up (up to 12 months), Incidence rate of major bleeding (as per International Society of Thrombosis and Haemostasis (ISTH) definition) during follow-up (up to 12 months), Incidence rate of clinically relevant non-major bleeding (as per ISTH definition) during follow-up (up to 12 months), All-cause mortality rate, Mean changes in patient-reported outcome measures (PROMs) from baseline to 6 and 12 months as assessed by functional scales (Patient reported Villalta-scale - PRV, Post-venous thromboembolism functional status - PVFS), and generic health-related and disease specific QOL questionnaires (EuroQoL-EQ-5D-5L, VEINES QOL/Sym, PEmb-QoL), Safety endpoints: 1.Number and incidence rate of gastrointestinal adverse events that result in study drug discontinuation 2.Number and incidence rate of muscle pain episodes that results in study drug discontinuation 3.Number and incidence rate of infections episodes leading to hospitalization. Other: renal insufficiency; neutropenia and/or neuropathy leading to study drug discontinuatio PTS (Villalta score ≥5) at 12 months

Начало: 23.04.2026 Възраст: от 18 г.

Italy Universita' Degli Studi G. D'Annunzio Di Chieti 2025-521836-12-00

Recruiting Phase 2

A randomized controlled, two-arm (1:1 ratio) Phase IIa trial to assess the efficacy and safety of obinutuzumab in treating adults with de novo minimal change disease

Kidney disease

Trial status: Authorised Time to remission (either complete or partial), Time to complete remission, Time to disease relapse, Change in Glucocorticoid Toxicity Index (GTI) from baseline to day 60, week 26 and 52, Change in urinary protein-to-creatinine ratio/albumin-to-creatinine ratio from baseline to week 26 and 52, Change in serum albumin from baseline to week 26 and 52, Kidney function as assessed by changes in 2021 race-free CKD-EPI estimated glomerular filtration rate (eGFR) from baseline to week 26 and 52, Patient-reported health–related QoL assessed by EuroQol 5-Dimensions 5-Levels Questionnaire (EQ-5D-5L), Predictors of disease relapse (independent of treatment assignment): Demographics, clinical characteristics, biological variables and histopathological characteristics, Safety endpoint: Serious adverse events (assessed by CTCAE v5; defined as grade ≥3) during the study period of 52 weeks, Safety endpoint: Adverse events of special interest (AESI) and infection events during the study period of 52 weeks, Safety endpoint: The proportion of patients with overall and mild hypogammaglobulinemia (

Начало: 23.04.2026 Възраст: от 18 г.

France, Germany Medizinische Universitaet Innsbruck 2025-520641-69-00

Recruiting Phase 1

A research study investigating the effect of NNC0497-0040 in healthy participants, participants with overweight or obesity, and participants with type 1 diabetes with overweight or obesity.

Type I diabetes

Trial status: Authorised

Начало: 23.04.2026 Възраст: 18–64 г.

Germany Novo Nordisk A/S 2025-523978-16-00

Recruiting Phase 2

A Phase 1/2 Open-Label, Single Ascending Dose, First-In-Human Study to Assess Safety and Tolerability of Endoscopic Ultrasound-Guided Pancreatic Infusion of RJVA-001 in Adults With Inadequately Controlled Type 2 Diabetes on Multiple Glucose-Lowering Agents.

Type 2 Diabetes

Trial status: Authorised 1. Change in transgene secretion and glycemic parameters., 2. Anti-AAV9 antibody titers, anti-GLP-1 antibody titers and enzyme-linked immunosorbent spot for AAV9 and GLP-1., 3. Digital polymerase chain reaction for AAV9 in samples., 4. Change from Baseline parameters using continuous glucose monitoring. Incidence, severity, dose-relationship of Adverse Events and changes in laboratory evaluations.

Начало: 23.04.2026 Възраст: от 18 г.

Netherlands Fractyl Health Inc. 2025-524438-24-00

Recruiting Phase 4

A randomized double-blind placebo-controlled study to demonstrate the efficacy of PMBL® sublingual tablets in reducing the incidence of respiratory tract infections in children aged 3-12 years (PIRTIK).

Respiratory Tract Infections

Trial status: Authorised - % of pts free of RTI during the overall study period - Mean duration in days per RTI during the overall study period (OST) – No. of days with RTI during the OST – No. of days of antibiotics use during the OST - Total no. of workdays lost by parents due to their child’s RTI during the OST – No. of physician consultations due to RTI or related complications – No. of antibiotic treatments (courses) for a respiratory event during the OST – No. of pts with (serious) AE and (serious) ADR Rate of Respiratory Tract Infections (RTIs): the number of RTIs experienced by a subject throughout the study (3 month-treatment period and 4 month-follow-up) will be assessed.

Начало: 23.04.2026

Poland Lallemand Pharma Europe filial af Lallemand Pharma AG S 2025-524212-11-00

Recruiting Phase 1

Phase I study of CDK8 inhibitor RVU120 in combination with everolimus in children with recurrent or progressive Group 3 or 4 medulloblastoma; MEDWAY

Medulloblastoma (recurrent or progressive)

Trial status: Authorised 1. PK parameters of RVU120 as a single agent and in combination with everolimus, including Cmax, AUCτ, tmax, AUC0 - ∞, t1/2 2. Ctrough of everolimus in combination with RVU120 3. Overall response rate (ORR), duration of response, progression-free survival (PFS), and overall survival (OS) in accordance with RAPNO guidelines, where applicable, stratified by molecular subgroup (G3 vs. G4) and MYC or MYCN expression in combination therapy of RVU120 and everolimus 1. Frequency and nature of AEs, SAEs and DLTs according to CTCAE v5.0 in RVU120 monotherapy and combination therapy with everolimus 2. MTD and/or RP2D of RVU120 as a single agent and in combination with everolimus

Начало: 23.04.2026

Poland Instytut Pomnik Centrum Zdrowia Dziecka 2025-524031-39-00

Recruiting Phase 3

Impact of Oral Semaglutide on Platelet Reactivity in Patients with Diabetes Mellitus or Overweight with High Risk or established Cardiovascular Disease: the SEMA-PLAT Study

Diabetes Mellitus Cardiovascular disease Overweight (BMI ≥27 kg/m²) Obesity (BMI≥30kg/m2)

Trial status: Authorised Changes between groups at different time points (T1, T2 and T3) in: • Markers of thrombus formation (T-TAS AUC, P-selectin, aGPIIbIIIa, PDMP) • Inflammatory markers (IL-1, IL-6); • Oxidative stress markers (H₂O₂, sNOX2-dp, HBA); • Endothelial function markers (NO, endothelin-1); • Autophagy markers (p62, LC3, ATG5). Change in platelet reactivity assessed by light transmission aggregometry [LTA] following ADP (2 and 5 μmol/L) and collagen (2 μg/mL) stimuli between groups at T3;

Начало: 23.04.2026 Възраст: от 18 г.

Italy Casa Di Cura Accreditata Istituto Chirurgico Ortopedico 2025-522486-29-01

Recruiting Phase 1

Phase I, first-in-human clinical trial to evaluate safety of infusion of STAb-T19 cells: genetically modified T lymphocytes secreting αCD19xαCD3 bispecific antibodies for malignant B-cell neoplasms

Malignant B-cell neoplasms

Trial status: Authorised

Начало: 22.04.2026 Възраст: от 18 г.

Spain Fundacion Para La Investigacion Biomédica Del Hospital 2025-524814-27-00

Recruiting Phase 4

Single-Dose Study in Healthy Participants to Compare the Bioavailability of One Film-Coated Mini-Tablet of Indapamide SR 1.5 mg versus One Film-Coated Tablet of Indapamide IR 2.5 mg Under Fasting Conditions, and to Compare the Bioavailability of One Film-Coated Mini-Tablet of Indapamide SR 1.5 mg Under Fasting versus Fed Conditions.

No medical condition.

Trial status: Authorised

Начало: 22.04.2026 Възраст: 18–64 г.

Portugal Institut De Recherches Internationales Servier IRIS 2026-526040-13-00

Recruiting Phase 2

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Finding Study of CX11 Tablets in Patients with Type 2 Diabetes Mellitus.

Type 2 Diabetes Mellitus

Trial status: Authorised 1. HbA1c < 7.0% 2. HbA1c ≤ 6.5% 3. Change of TIR on CGM from baseline 4. Change in FPG from baseline 5. Change in body weight from baseline 6. Percent change in body weight from baseline 7. Body weight loss ≥ 5% 8. Body weight loss ≥ 10% 8. Body weight loss ≥ 10%, 9. Change in SBP and DBP from baseline 10. Number of level 2 hypoglycemic episodes or severe hypoglycemic episodes 11. TEAE & AESI; 12. Population PK parameters Change in HbA1c from baseline

Начало: 22.04.2026 Възраст: от 18 г.

Poland Corxel Pharmaceuticals Inc. 2025-524514-28-00

Recruiting Phase 1

Clinical Study to Evaluate the Effects of Cevostamab in Patients with Lupus with or without Active Lupus Nephritis

Systemic Lupus Erythematosus (SLE) With or Without Active Lupus Nephritis (LN)

Trial status: Authorised

Начало: 22.04.2026 Възраст: от 18 г.

France, Italy Genentech Inc. 2025-522904-26-00

Recruiting Phase 2

COLOMBE - A multicentre, single arm, phase 1/2 study, aiming to assess the safety and efficacy of nivolumab and imiquimod combination in vulvar squamous cell carcinoma patients

Vulvar Squamous Cell Carcinoma (VSCC) patients

Trial status: Authorised Pathological response: The pathological tumor response (pTR) is defined as the presence of tumor cell necrosis and keratinous debris with giant cell/histiocytic reaction, quantified as a percentage of the overall tumor bed (area pathologic response/area pathologic response plus viable tumor): pTR-0 (

Начало: 22.04.2026 Възраст: от 18 г.

France Centre Leon Berard 2025-524759-29-00

Recruiting Phase 1

A Phase I study to evaluate the safety and dosimetry of imaging with 68Ga-OncoACP3 in prostate cancer.

Patients with prostate cancer with: - suspected metastasis who are candidates for initial definitive therapy - suspected recurrence based on elevated serum prostate-specific antigen (PSA) level (i.e. a progressive and confirmed serum PSA level > 0.2 ng/mL) - metastatic disease who might be candidates for treatment with 177Lu-labelled PSMA ligands

Trial status: Authorised

Начало: 22.04.2026 Възраст: от 18 г.

Italy Philogen S.p.A. 2025-524594-16-00

Recruiting Phase 2

Exploratory study on the effect of Rimonabant on hand function in patients with spinal cord injury (RIMOHANDOPEN)

Spinal cord injury

Trial status: Authorised 6-Minute Walk Test (6MWT): measures the distance a participant can walk in six minutes, providing an index to measure fatigue, endurance and functional walking capacity, 10-Meter Walk Test (10MWT): measures the time taken to walk 10 meters at a comfortable or maximal pace, used to assess motor function through walking speed, fatigue and endurance, Berg Balance Scale (BBS): evaluates static and dynamic balance through 14 functional tasks, providing a quantitative assessment of fall risk and postural control, Walking Index for Spinal Cord Injury II (WISCI-II): assesses walking ability based on the level of assistance, use of assistive devices and need for support, yielding a score reflecting functional ambulation capacity., Finger Tapping Test (FTT): measures motor speed and coordination by recording the number of finger taps within a set time period, Box and Block Test (BBT): assesses gross manual dexterity by counting the number of blocks transferred from one compartment to another in 60 seconds, Nine-Hole Peg Test (9HPT): measures fine manual dexterity by timing how long it takes to place and remove nine pegs from a boardNine-Hole Peg Test (9HPT): measures fine manual dexterity by timing how long it takes to place and remove nine pegs from a board, Dynamometry: measures handgrip strength by recording the maximum force exerted during a grip using a handheld dynamometer., Upper Extremity Motor Score (UEMS): evaluates motor strength of five key upper limb muscles bilaterally. This data is obtained from the ISNCSCI scale, Functional Reach Test (FRT): assesses upper limb functional reach and dynamic balance by measuring the maximum distance an individual can reach forward without losing stability, Borg CR10 Scale: assesses perceived exertional fatigue immediately after the 6MWT and FTT, providing a subjective measure of effort intensity, Visual Analogue Scale for Fatigue (VAS-F): assesses perceived fatigue intensity by having participants rate their level of fatigue after FTT, Fatigue Severity Scale (FSS): evaluates fatigue severity over the previous week. Scores ≥ 4 indicate clinically significant fatigue, Multidimensional Fatigue Inventory (MFI-20): measures five dimensions of fatigue, offering a comprehensive assessment of fatigue impact, Breathing test: test designed to evaluate the respiratory function and lung capacity of the participant., Oximetry: non-invasively measures blood oxygen saturation and heart rate, providing a quick indicator of the participant's respiratory status, Heart rate: non-invasive measurement used to monitor cardiovascular response and detect potential abnormalities in heart function., Blood pressure (systolic and diastolic): non-invasive assessment providing key information on vascular resistance and overall cardiovascular health., International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI): determines the neurological level and completeness of spinal cord injury through systematic assessment of motor and sensory function, Transcranial magnetic stimulation (TMS): evaluate corticospinal excitability and motor pathway integrity registering motor evoked potentials (MEPs)., Somatosensory evoked potentials (SEPs) via electrical stimulation: assess sensory pathway conduction and integrity by recording cortical responses to peripheral nerve electrical stimulation., Spinal Cord Independence Measure (SCIM-III): measures functional independence in activities of daily living, mobility, and sphincter management, providing an index of overall functional recovery., Medical Outcomes Study Sleep Scale (MOS-SS): assesses multiple aspects of sleep, including quality, disturbances, somnolence, and adequacy, over the previous four weeks., Patient Global Impression of Change (PGIC): captures the patient’s subjective perception of overall improvement or deterioration since the beginning of the study., Recording and assessment of adverse events (AEs) occurring during treatment, serious adverse events (SAEs), and adverse events of special interest (AESIs)., Clinically significant changes in physical examination, biochemical parameters, vital signs., Clinically significant changes in subjective pain perception, assessed using the Visual Analogue Scale (VAS-P)., Clinically significant changes in the level of muscle spasticity, assessed using the Modified Ashworth Scale (MAS)., Clinically significant changes in the frequency of muscle spasms, assessed using the Penn Spasm Frequency Scale (PSFS)., Clinically significant changes in mood, specifically depression and anxiety, assessed using the Beck Depression Inventory-II (BDI-II) and the Hospital Anxiety and Depression Scale (HADS)., Suicide risk, assessed using C-SSRS. The primary endpoint is defined as the change in the total GRASSP score, or in any of its three dimensions, between baseline and the end of rimonabant treatment.

Начало: 22.04.2026 Възраст: от 18 г.

Spain Sinfatin S.L. 2025-524279-22-00

Recruiting Phase 1

A FIRST-IN-HUMAN (FIH) PHASE 1/2 STUDY TO ASSESS SAFETY, TOLERABILITY, AND PRELIMINARY ANTI-TUMOR ACTIVITY OF REGN17372, AN ANTI-GPRC5D X ANTI-CD28 COSTIMULATORY BISPECIFIC MONOCLONAL ANTIBODY, IN COMBINATION WITH LINVOSELTAMAB, AN ANTI-BCMA X ANTI-CD3 BISPECIFIC MONOCLONAL ANTIBODY, IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Relapsed/Refractory Multiple Myeloma

Trial status: Authorised Phase 1 and Phase 2: Concentrations of REGN17372 in serum, Phase 1 and Phase 2: Concentrations of linvoseltamab in serum, Phase 1 and Phase 2: Occurrence of Anti-Drug Antibodies (ADA) to REGN17372, Phase 1 and Phase 2: Magnitude of ADA to REGN17372, Phase 1 and Phase 2: Incidence of ADA to linvoseltamab, Phase 1 and Phase 2: Magnitude of ADA to linvoseltamab, Phase 1 and Phase 2: Objective Response Rate (ORR) as assessed by IMWG response criteria as determined by the investigator, Phase 1 and Phase 2: Complete response (CR) as assessed by IMWG response criteria as determined by the investigator, Phase 1 and Phase 2: VGPR as assessed by IMWG response criteria, as determined by the investigator, Phase 1 and Phase 2: Duration of Response (DOR) as assessed by IMWG criteria as determined by the investigator, Phase 1 and Phase 2: Progression Free Survival (PFS) as assessed by IMWG criteria as determined by the investigator, Phase 1 and Phase 2: Minimal Residual Disease (MRD) negative status (at 10^-5) in participants in CR or better, Phase 1 and Phase 2: Overall Survival (OS), Phase 1: ORR as assessed using the IMWG response criteria as determined by the investigator in patients receiving combination study drugs, Phase 1:VGPR assessed using IMWG criteria as determined by the investigator in patients receiving combination study drugs, Phase 2: Incidence of TEAEs, Phase 2: Severity of TEAEs, Phase 2: Change from baseline in European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30) Global Health Status / Quality of Life (GHS/QoL), Phase 2: Change from baseline in EORTC QLQ-C30 Physical Functioning (PF), Phase 2: Change from baseline in EORTC QLQ-C30 Role Functioning (RF), Phase 2: Change from baseline in EORTC QLQ-C30 pain, Phase 2: Change from baseline in EORTC QLQ-C30 fatigue, Phase 2: Time to definitive deterioration in EORTC QLQ-C30 GHS/QoL, Phase 2: Time to definitive deterioration in EORTC QLQ-C30 PF, Phase 2: Time to definitive deterioration in EORTC QLQ-C30 RF, Phase 2: Time to definitive deterioration in EORTC QLQ-C30 pain, Phase 2: Time to definitive deterioration in EORTC QLQ-C30 fatigue, Phase 2: Time to first improvement in EORTC QLQ-C30 GHS/QoL, Phase 2: Time to first improvement in EORTC QLQ-C30 PF, Phase 2: Time to first improvement in EORTC QLQ-C30 RF, Phase 2: Time to first improvement in EORTC QLQ-C30 pain, Phase 2: Time to first improvement in EORTC QLQ-C30 fatigue, Phase 2: Change from baseline in EORTC QLQ-Multiple Myeloma Module (MY20) Disease Symptoms (DS), Phase 2: Time to definitive deterioration in EORTC QLQ-MY20 DS, Phase 2: Time to first improvement in EORTC QLQ-MY20 DS, Phase 2: Change from baseline in EORTC QLQ-MY20 Treatment Side Effects (TSE), Phase 2: Time to definitive deterioration in EORTC QLQ-MY20 TSE, Phase 2: Time to first improvement in EORTC QLQ-MY20 TSE, Phase 2: Change from baseline in EuroQoL-5 Dimensions, 5-level Questionnaire (EQ-5D-5L) Visual Analogue Score (VAS) (EQ-5D-5L VAS), Phase 2: Time to definitive deterioration in EQ-5D-5L VAS, Phase 2: Time to first improvement in EQ-5D-5L VAS, Phase 2: Patient-reported overall impact of treatment toxicity measured by Functional Assessment of Cancer Therapy (FACIT) Item GP5, Phase 2: Patient-reported tolerability as measured by the Patient Reported Outcome-Common Terminology Criteria for Adverse Events (PRO-CTCAE) Phase 1: Occurrence of Dose Limiting Toxicities (DLTs) from the first dose of REGN17372 in combination with linvoseltamab, Phase 1: Occurrence of Treatment Emergent Adverse Events (TEAEs) associated with REGN17372 in combination with linvoseltamab, Phase 1: Severity of TEAEs associated with REGN17372 in combination with linvoseltamab, Phase 2: Very Good Partial Response (VGPR) or better as determined by the investigator using the International Myeloma Working Group (IMWG) response criteria in patients receiving combination study drugs, Phase 2: VGPR or better as determined by the investigator using the IMWG response criteria in patients receiving Linvoseltamab monotherapy, Phase 2: Partial Response (PR) or better as determined by the investigator using the IMWG response criteria in patients receiving combination study drugs, Phase 2: PR or better as determined by the investigator using the IMWG response criteria in patients receiving Linvoseltamab monotherapy

Начало: 22.04.2026 Възраст: от 18 г.

Greece Regeneron Pharmaceuticals Inc. 2025-522776-93-00

Recruiting Phase 2

A Multicentre, Parallel-group, Phase II, Randomised, Double-blind, 4 Arm Study to Evaluate Efficacy and Safety of AZD1163 in Participants with Moderately-to-Severely Active Rheumatoid Arthritis (LaunchPAD-RA)

Rheumatoid arthritis

Trial status: Authorised Percentage of Participants Achieving American College of Rheumatology Response Criteria 20 (ACR20) at Week 12 - Percentage of Participants Achieving ACR50 at Week 12 - Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 12 - Change From Baseline in Simplified Disease Activity Index (SDAI) at Week 12, AZD1163 concentrations in serum., ADA (incidence, prevalence, and titres) Change From Baseline in Disease Activity Score-C-Reactive Protein (DAS28-CRP) at Week 12

Начало: 22.04.2026 Възраст: от 18 г.

Germany, Hungary, Poland +1 AstraZeneca AB 2025-522076-85-00

Recruiting Phase 2

ROSETTA HCC-206: An Open-Label, Multi-Center, Randomized Phase 1/2 Study of Pumitamig Alone or In Combination with Ipilimumab in Participants with First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC)

Advanced or unresectable Hepatocellular Carcinoma (HCC)

Trial status: Authorised To check how many people’s liver cancer gets much smaller or goes away (cancer shrinkage)., To count how many people have problems or serious problems from the medicines, including those who stop treatment or die because of them (safety), To measure how much pumitamig is in the blood after treatment and before the next dose (pumitamig levels)., To measure how much ipilimumab is in the blood before the next dose (ipilimumab levels)., To see if people’s bodies make fighters against the medicines (anti-drug antibodies)., To see how long people live without the cancer getting worse, and how long the cancer stays smaller or goes away (progression delay (PFS, Progression-Free Survival and duration (DOR, Duration of Response). The main goal of phase 1 will check and count for how many people have problems or serious problems from the medicine, if anyone must stop taking it because of these problems, and if any problems cause death., The main goal of phase 2 will be to check and count how many people's liver cancer gets much smaller or completely goes away with the treatment (OR (Objective Response) confirmed CR (complete response) or PR (partial response)).

Начало: 22.04.2026 Възраст: от 18 г.

Italy, Poland Bristol-Myers Squibb Services Unlimited Company 2025-523602-33-00

Recruiting Phase 2

A phase II trial evaluating treatment intensification with Ezabenlimab in patients with PD-L1–expressing, locally advanced head and neck squamous cell carcinoma (LA-HNSCC) with minimal residual disease (MRD) as detected by circulating tumor DNA (ctDNA) after curative-intent chemoradiation

Locally advanced head and neck squamous cell carcinoma (LA-HNSCC)

Trial status: Authorised Frequency and severity of TEAEs, irAEs, IRRs, serious AEs (SAE) TEAE/SAEs leading to dose delays, withdrawal or death. Clinically significant changes in laboratory, vital signs, and safety assessment parameters., Change from baseline in QoL as assessed by the EORTC QLQ-C30 and QLQ-HN43. Participant-reported frequency and severity of symptomatic toxicity based on PRO-CTCAE and FACT-GP5 and frequency distribution of PGIS/PGIC over time., Correlation of post-CRT ctDNA-based MRD status, ctDNA longitudinal changes (such as molecular response) with clinical activity and response. Change of ctDNA status (approx. every 3 months)., OS defined as the time from post-CRT MRD assessment to death from any cause., EFS is defined as the time from post-CRT MRD assessment to disease progression, recurrence, or death from any cause, whichever comes first EFS rate at 2-years in MRD-positive patients (interventional cohort) where EFS rate is defined as the proportion of patients who have not experienced any EFS event at 2 years after MRD assessment (i.e., after CRT).

Начало: 22.04.2026 Възраст: от 18 г.

Belgium Cliniques Universitaires Saint-Luc 2025-523575-36-00

Recruiting Phase 4

A research study to compare blood levels of cagrilintide after multiple doses of different versions of cagrilintide in adults with overweight or obesity

obesity

Trial status: Authorised

Начало: 21.04.2026 Възраст: 18–64 г.

Germany Novo Nordisk A/S 2025-521384-12-00

Recruiting Phase 3

J3R-MC-YDAL - A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Persistent Obesity or Overweight Treated With a Weekly Incretin, With and Without Type 2 Diabetes

Overweight Obesity

Trial status: Authorised Percent Change from Baseline in Body Weight [Time Frame: Baseline, Week 64]

Начало: 21.04.2026 Възраст: от 18 г.

Belgium, Czech Republic, Spain Eli Lilly & Co. 2025-523659-73-00

1 2 3 … 15